Northwest Biotherapeutics (NWBO) Receives $4.5M Investment in Support of Cancer Treatment Technology
Northwest Biotherapeutics, a biotech company focused on immunotherapy cancer treatments, announced it has received a $4.55 million equity investment on June 28, 2011, from the Richard M. Schulze Family Foundation. The Foundation has long focused on medical research and treatment breakthroughs, and supports basic research at universities, and clinical programs at medical centers such as the University of Minnesota and the Mayo Clinic. The Foundation expressed its favor with Northwest’s lead product candidate, DCVax®-L which is currently in phase II clinical trials for treatment of Glioblastoma multiforme (GBM), the most lethal form of brain cancer. In the study, patients receiving…